DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactOrders & Deals

Vilin Bio Med Limited — Amalgamation/Merger

NSE 55 min ago·11 Sept 2026, 9:44 am

Vilin BIO MED

Vilin Bio Med Limited has announced a proposed merger with another entity, a move that will combine the two companies into a single legal entity. This amalgamation process is a strategic step to consolidate operations, resources, and market presence under one unified structure.

For investors, this development signals a potential shift in the company's corporate governance and business strategy. The merger could lead to operational efficiencies, but it also brings uncertainties regarding management integration and the long-term impact on the stock's performance.

Investors should monitor the regulatory approvals and the final details of the amalgamation. Keeping an eye on the company's future outlook post-merger will be crucial to understanding how this consolidation might affect the stock's value in the market.